Biomaneo

Biomaneo operates in the biomedical sector, focusing on providing integrative and scalable analysis solutions tailored to client needs. The company is involved in automating biological screening processes, enhancing efficiency, and reducing mortality rates while minimizing analysis costs. Biomaneo's core product, the NeoSickle solution, is utilized in 80% of French sample analyses, highlighting its significant market presence. The business model revolves around offering advanced screening solutions that cater to clinical applications, with a strong emphasis on data processing and interpretation assistance. Biomaneo serves healthcare institutions and collaborates with scientific organizations, as evidenced by its partnership with the Centre de Prise en charge du Nourrisson et de la Femme Enceinte. The company generates revenue through the sale and implementation of its screening solutions, supported by financial backing from entities like BFC Croissance Innovation. Biomaneo's commitment to quality is underscored by its ISO 13485:2016 certification, ensuring high standards in its operations. The company also invests in human capital, focusing on training young professionals to strengthen its workforce.

Keywords: biomedical, screening, NeoSickle, clinical, analysis, efficiency, cost-effective, data processing, healthcare, collaboration